Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E60.24 EPS (ttm)1.12 Insider Own0.10% Shs Outstand1.59B Perf Week2.40%
Market Cap107.49B Forward P/E13.65 EPS next Y4.94 Insider Trans-9.58% Shs Float1.57B Perf Month1.47%
Income1.82B PEG4.04 EPS next Q1.05 Inst Own72.60% Short Float1.67% Perf Quarter12.41%
Sales20.44B P/S5.26 EPS this Y-57.20% Inst Trans-0.31% Short Ratio2.14 Perf Half Y1.12%
Book/sh0.86 P/B78.45 EPS next Y16.86% ROA6.50% Target Price72.73 Perf Year28.68%
Cash/sh4.97 P/C13.56 EPS next 5Y14.90% ROE56.00% 52W Range50.19 - 69.66 Perf YTD4.74%
Dividend2.04 P/FCF99.16 EPS past 5Y-17.80% ROI16.80% 52W High-3.14% Beta-
Dividend %3.02% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin79.40% 52W Low34.42% ATR1.19
Employees26000 Current Ratio1.40 Sales Q/Q10.50% Oper. Margin21.50% RSI (14)71.25 Volatility1.57% 1.56%
OptionableYes Debt/Eq11.09 EPS Q/Q4.90% Profit Margin8.90% Rel Volume1.05 Prev Close67.38
ShortableYes LT Debt/Eq7.76 EarningsApr 23 BMO Payout155.30% Avg Volume12.29M Price67.47
Recom2.20 SMA203.31% SMA508.01% SMA20011.68% Volume12,885,048 Change0.13%
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
May-28-15 03:11PM  Pfizer: Split Decision Could Come Earlier Than You Think at Barrons.com
02:51PM  AbbVie: The Future's So Hazy I Can't Wear Shades at Barrons.com
12:01PM  AbbVie (ABBV) Stock Is the 'Chart of the Day' at TheStreet
11:26AM  Breakout Watch: AbbVie Testing New Buy Point at Investor's Business Daily
09:42AM  How to Trade 3 of the Market's Most Active Stocks at TheStreet
09:30AM  Short Sellers More Selective on Big Pharma Stocks at 24/7 Wall St.
09:00AM  Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers PR Newswire
08:56AM  Pharmalot.. Pharmalittle.. Good Morning: We're Catching up on J&J, AbbVie, Teva and Lots More!! at The Wall Street Journal
08:52AM  Morgan Stanley Calls AbbVie 'Unpredictable' With 'Upside'
May-27-15 06:59PM  IBD Market Wrap - 05/27/15
01:12PM  AbbVie Is Buying Back $5 Billion in Stock. Hurray? at Insider Monkey
11:42AM  AbbVie (ABBV) Stock Gains on Bullish JPMorgan Note at TheStreet
10:37AM  JPMorgan: Buy AbbVie, Low Valuation Belies EPS Growth Potential at Barrons.com
06:55AM  AbbVie Accelerates Share Buybacks at The Wall Street Journal
06:05AM  ABBVIE INC. Files SEC form 8-K, Other Events
May-26-15 07:00PM  AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis PR Newswire
05:36PM  NWQ's First-Quarter Buys and Adds Affect Portfolio
04:31PM  Ambarella Leads 3 Top Stocks Bucking The Sell-Off
02:27PM  Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck at TheStreet
01:21PM  This Medical Stock Refuses To Fall With Major Stock Indexes at Investor's Business Daily
12:42PM  AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase at TheStreet
11:15AM  Abbvie completes $21 billion buyout of Pharmacyclics
08:51AM  ABBVIE INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statement
08:30AM  AbbVie Completes Acquisition of Pharmacyclics PR Newswire
May-22-15 09:15AM  Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy at 24/7 Wall St.
08:00AM  AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics PR Newswire
May-21-15 12:12PM  Abbvie specifies breakdown of $21 billion Pharmacyclics deal
08:27AM  What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
08:00AM  AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics PR Newswire
May-20-15 03:34PM  Glenview Repeats AbbVie Bull Stance, Shuts Fund To Newbies
May-19-15 10:08AM  Healthcare AM Winners and Losers: May 19, 2015
09:15AM  Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays at Insider Monkey
May-18-15 06:16PM  Cramer: Merger mania-Buckle up for more! at CNBC
12:40PM  AbbVie's Humira Gets FDA Orphan Status for Skin Disease - Analyst Blog
May-16-15 11:05AM  Gaming the Risk-to-Reward Scenario in the IGATE Transaction
May-15-15 04:43PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. PR Newswire
01:04PM  ABBVIE INC. Financials
09:44AM  AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS) PR Newswire
09:06AM  Investment-Grade Bond Funds See Outflows in the Week Ended May 8
May-14-15 11:50PM  The drugs to watch in fight against cancer at Financial Times
06:27PM  Galapagos Receives a Rousing Welcome on Its First Day of Trading at TheStreet
01:52PM  What The Travails Of The UK's Largest Grocer Can Teach The Pharmaceutical Industry at Forbes
11:32AM  Looking for Investment Ideas? These Wall Street Heavyweights Just Gave You a Bunch at TheStreet
11:06AM  AbbVie Completes the 3rd-Highest High-Grade Issuance in 2015
08:59AM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre
12:39AM  Bristol and AbbVies Experimental Drug Delayed Progression of Blood Cancer at The Wall Street Journal
May-13-15 05:10PM  Experimental Drug Delayed Blood Cancer Progression, Study Says at The Wall Street Journal
05:00PM  Bristol, AbbVie drug extends multiple myeloma remission-study
08:15AM  AbbVie to Present at UBS Global Healthcare Conference PR Newswire
12:01AM  500,000 Americans spend $50K on medicine each year at CNBC
May-12-15 06:34PM  Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs at The Wall Street Journal
01:45PM  IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers
09:50AM  Short Sellers Keep Strong Bets Against Big Pharma at 24/7 Wall St.
08:02AM  AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 PR Newswire
May-11-15 05:25PM  ABBVIE INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
12:39PM  Gilead Leads HCV Race Despite Competition From AbbVie
10:26AM  Borrowers warned: Don't be fooled by high grade market resilience Reuters
09:05AM  Parsing the iGATE-Capgemini Material Adverse Effect Clause, Part 2
08:30AM  9 Hot (Or Not) IPOs Scheduled To Debut This Week
08:00AM  AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting PR Newswire
May-10-15 11:31AM  GlaxoSmithKline chief seeks immunity from sector's herd mentality at Financial Times
May-08-15 04:41PM  ABBVIE INC. Files SEC form 10-Q, Quarterly Report
02:17PM  2 reasons we're not in biotech bubble: Pro
11:10AM  Best U.S. Pharma Picks, Big and Small at Barrons.com
May-07-15 04:50PM  Prescription Fish Oil Maker Hires Top Lawyer To Sue FDA On First Amendment Grounds at Forbes
04:15PM  What's in Store for Repros (RPRX) this Earnings Season? - Analyst Blog
04:12PM  ABBVIE INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
03:50PM  The Basics of iGATE
08:04AM  Is biotech in a bubble?
May-06-15 03:33PM  Cablevision Eyes Consolidation, Biotech Seen Nearing Bubble at TheStreet
02:40PM  Synageva BioPharma: Another Winning Lottery Ticket For Investors at Forbes
01:30PM  Alexion Pharmaceutical's Premium for Synageva Is Fourth-Highest on Record at The Wall Street Journal
12:13PM  Another mega deal in biotech
10:00AM  Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks at 24/7 Wall St.
09:03AM  Gilead to Buy EpiTherapeutics for $65 Million at The Wall Street Journal
08:19AM  Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation at noodls
08:19AM  AbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference at noodls
07:30AM  Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation PR Newswire
07:00AM  AbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference PR Newswire
May-05-15 05:07PM  AbbVie Warps Up Large Debt Sale at The Wall Street Journal
02:32PM  Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. at Barrons.com
02:13PM  AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis at noodls
01:13PM  Ira Sohn 2015: The hidden gems
12:20PM  AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis PR Newswire
10:53AM  Macy's new off-price project, Periscope CEO speaks
10:50AM  Top Credit Suisse Major Pharma Stock Picks to Buy at 24/7 Wall St.
10:30AM  Pfizer, other drug giants to drive biotech
10:07AM  AbbVie Inc. -- Moody's rates AbbVie's new notes Baa1; negative outlook at Moody's
May-04-15 04:36PM  U.S. stocks rose moderately...
03:34PM  Gilead Sciences Earnings Analysis: By the Numbers
03:13PM  Stocks Hover at Highs; Oil Closes Below $59 on Weak China Demand at TheStreet
03:00PM  Glenviews Robbins Recommends AbbVie With Target of $90 at Bloomberg
02:45PM  Glenview's Larry Robbins believes AbbVie 'under appreciated' at MarketWatch
02:45PM  Live from Sohn: Glenview's Robbins Likes AbbVie, Brookdale Senior Living at Barrons.com
May-01-15 06:35PM  AbbVie Again Extends Exchange Offer to Acquire Pharmacyclics at The Wall Street Journal
05:49PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. at noodls
04:59PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. PR Newswire
10:20AM  Gilead Tops Q1 Earnings Estimates, 2015 Outlook Revised - Analyst Blog
Apr-30-15 04:23PM  Gilead Profit Soars on Hepatitis C Drugs Sales at The Wall Street Journal
Apr-29-15 03:08PM  Gilead Sciences: Getting Ready for Earnings at Barrons.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM